Radiotherapy to Bone Has Utility in Multifocal Metastatic Renal Carcinoma

Reichel LM, Pohar S, Heiner J, Buzaianu EM, Damron TA.
Radiotherapy to Bone Has Utility in Multifocal Metastatic Renal
Carcinoma.
Clin Orthop Relat Res. 2007 Apr 12; [Epub ahead of print]
PMID: 17438472 [PubMed - as supplied by publisher]
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=17438472&dopt=Abstract>

"Renal cell carcinoma metastases to bone are classically
considered radioresistant. We reviewed 28 patients who
underwent irradiation for metastatic renal cell carcinomas to
bone to test the hypothesis that irradiation of renal
metastases to bone provides adequate palliation in carefully
selected patients. Metastases were multifocal in all patients.
All patients were followed until death. Overall, 36 index
radiotherapy treatments were given as palliative initial
treatment for 36 osseous metastatic sites. Twenty-five of 36
sites (69.5%) had no subsequent radiotherapy. Eight sites
(22.2%) underwent repeat radiotherapy at a mean 28.9 weeks
after treatment. Two (5.6%) additional sites underwent surgery
at the site at an average 74 weeks later, and a pathologic
fracture occurred at one (2.8%) site 3 weeks after irradiation.
Overall, 33 of 36 (91.7%) sites had only radiotherapy as their
source of palliation. Median times to return to pretreatment
pain and functional levels, however, were 2 months and 1 month,
respectively. Radiotherapy to osseous sites appears to control
pain for the short term and generally prevents fractures and
avoids the need for surgery in renal cell carcinoma patients
with multiple bone metastases.Level of Evidence: Level IV,
therapeutic study. See the Guidelines for Authors for a
complete description of levels of evidence."


--
Matti Narkia
.

Relevant Pages